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Background: According to the Pakistan Demographic and Health Survey from 2006–2007, the maternal mortality
ratio in rural areas is 319 per 100,000 live births. Postpartum hemorrhage is the leading cause of maternal deaths
in Pakistan. The objectives of the study were to document the feasibility of distribution of misoprostol tablets
by community-based providers mainly traditional birth attendants and acceptability and use of misoprostol by
women who gave birth at home.
Methods: A quasi-experimental design, comprising intervention and comparison areas, was used to document
the acceptability of providing misoprostol tablets to pregnant women to prevent postpartum hemorrhage in the
rural community setting in Pakistan. Data were collected using structured questionnaires administered to women
before and after delivery at home and their birth attendants.
Results: Out of 770 women who delivered at home, 678 (88%) ingested misoprostol tablets and 647 (84%)
ingested the tablets after the birth of the neonate but prior to the delivery of the placenta. The remaining women
took misoprostol tablets after delivery of the placenta. Side effects were experienced by 40% of women and were
transitory in nature. Among women who delivered at home, 80% said that they would use misoprostol tablets
in the future and 74% were willing to purchase them in the future.
Conclusions: Self-administration of misoprostol in the home setting is feasible. Community-based providers, such
as traditional birth attendants and community midwives with proper training and counseling, play an important
role in reducing postpartum hemorrhage. Proper counseling and information exchange are helpful for introducing
new practices in resource-constrained rural communities. Until such a time that skilled birth attendance is made
more universally available in the rural setting, alternative strategies, such as training and using the services of
traditional birth attendants to provide safe pregnancy care, must be considered.
Keywords: Postpartum hemorrhage, Home-based deliveries, Rural communities, Traditional birth attendants,
Misoprostol, PakistanBackground
Pakistan is among the few countries in South Asia that
continues to have poor reproductive health indicators.
Although there have been some improvements in recent
years, maternal mortality figures in Pakistan remain
high. Because of limited access to health facilities, ap-
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reproduction in any medium, provided the orhome, where a traditional birth attendant (TBA or dai)
or a family member usually attends the delivery [1].
Among the major causes of maternal deaths, postpar-
tum hemorrhage (PPH) is the most common. According
to the Pakistan Demographic and Health Survey of
2006–2007, 27.2% of maternal deaths were caused by
PPH [1].
To prevent PPH, injectable oxytocin is recommended
at the time of delivery as per routine. Oxytocin requires
storage in a cool temperature (5–25°C), and can only be
kept outside these temperatures for short durations. To. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in safe injection practices and the availability of sterile
syringes and needles are required [2].
Misoprostol, a prostaglandin E1, acts as an alternative
uterotonic to the injectable drug oxytocin and is avail-
able in tablet form. Misoprostol has been found to be
effective in controlling, as well as preventing, PPH [3,4].
Misoprostol is inexpensive, does not require any special
conditions for its storage, and its tablet form can be easily
administered by a community health care provider, a
TBA, and even the woman herself who has just delivered.
Results from a study in Egypt recommend the use of
misoprostol, even in the hospital setting if there are
staff shortages, refrigeration issues and/or high caseloads,
because misoprostol offers the advantage of a one-drug
regimen, stability, and easy administration, compared
with injectable uterotonics [5]. Misoprostol causes occa-
sional side effects, which include shivering and fever
[4,6-8]. The use of misoprostol has been recommended
by the United States Pharmacopoeia Expert Committee
for the Prevention of PPH, especially in settings where
injectable uterotonic drugs are not available [9]. Miso-
prostol has also been added to the WHO essential drugs
list [10].
In Pakistan, two research studies examined misopros-
tol use, conducted in hospital and community settings.
Both studies were carried out by Aga Khan University.
One of the studies was a hospital-based treatment-
placebo-controlled trial in which 600 μg of misoprostol
or a matching placebo was given sublingually in addition
to standard PPH treatment with injectable oxytocics [6].
The results supported adjunct use of misoprostol, but
there were no significant differences between the interven-
tion (oxytocin and misoprostol) and comparison (oxytocin-
placebo) groups. The trial had to be terminated because
the PPH rate was low. Another community-based pla-
cebo-controlled trial was conducted in Chitral in the
northern areas where TBAs were used to provide 600 μg
of misoprostol orally to women shortly after they gave
birth. The results showed that oral misoprostol reduced
the rate of PPH by 24% compared with the placebo.
Referrals for higher-level care during the immediate
postpartum period were similar following administration
of misoprostol (1.7%) [11].
The Population Council, as a consortium partner of
the USAID-sponsored Pakistan Initiative for Mothers
and Newborns (PAIMAN), undertook an operations re-
search project in two districts of Pakistan to assess the
feasibility of home administration of misoprostol for the
prevention of PPH in rural Pakistan. The purpose of
undertaking the study was based on the premise that
such an intervention has the potential to provide a
model for more effective safe motherhood interventions
in rural areas.The current study had the following objectives: to
document the feasibility of distribution of misoprostol
by community-based providers, including TBAs (called
dais in Pakistan), in a home setting; to assess the accept-
ability and use of misoprostol by pregnant women for
the prevention of PPH when administered at home; to
identify the common side effects of misoprostol; and
to determine the reduction in demand for referral due to
PPH after oral ingestion of misoprostol.
Methods
A quasi experimental design was used comprising inter-
vention and comparison areas (see below for more
detail). The study was conducted in the districts of
Dadu in Sindh Province and Khanewal in Punjab from
October 2009 to September 2010. Both districts were
focus districts of the PAIMAN project.
Participants and data collection
Pregnant women living in the selected union councils of
Khanewal and Dadu districts who were 15–49 years of
age and intended to deliver at home, were willing to par-
ticipate in the study, and would be delivering during the
study period were included in the study. Selection cri-
teria of eligible pregnant women varied in different vil-
lages depending on when registration occurred. When
registration started in the beginning of the study, women
in their second and third trimesters were included, while
in villages where registration was performed later in
the study, women only in their third trimester were
included. The date of delivery was estimated using the
Expected Date of Delivery Calculator wheel.
Sample size/sample size estimation
Currently, the PPH rate is estimated to be 11% of live
births globally [12]. For a developing country, such as
Pakistan, we expected this to be in the range of 10-15%.
We expected that this rate could be reduced by half
(to 5–7%) with the introduction of misoprostol. We also
assumed that half of the women with PPH would be re-
ferred irrespective of the project area. Therefore, in the
comparison areas, approximately half of the women with
PPH (7%) would be referred, while in the intervention
areas where the PPH rate was expected to be 5–7%,
referral would be reduced by half (3%). We calculated
the sample size with α at 5% and the power of the study
at 80%. We determined that a minimum of 780 deliver-
ies in each of the two groups was required to test the
difference of a 50% reduction in reported PPH [13].
Six union councils in Dadu district and seven in
Khanewal closest to the selected referral health facilities
were included in the study to meet the required sample
size. In Khanewal district, seven union councils were
selected, with four to serve as intervention areas and
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were selected, with three each to serve as intervention
and comparison areas. A union council has a population
of approximately 25–30,000 people. Union councils were
selected to avoid diffusion among the intervention and
comparison areas.
Study phases
I. Creating community awareness regarding study
objectives
The study consisted of two phases. The first phase
involved community awareness and family education,
through group interaction and individual counseling
with pregnant women and their family members. These
were carried out in separate sessions. At the time of
registration, each identified pregnant woman and her
family members (in both the comparison and interven-
tion areas), were given a briefing on birth preparedness
and obstetric danger signs using a pictorial booklet. For
women and their attendants in the intervention areas,
the briefing also included information regarding the use
of misoprostol, including correct timing, dosage and its
side effects. One month prior to the expected date of
delivery, the women were interviewed to assess retention
of knowledge. Fifteen days before the expected delivery
date, the women were again briefed on the information
provided earlier along with the information on referral
facilities. During this visit, clean delivery kits were given
to the women in both areas. In the intervention areas,
the kits also contained three tablets of 200 μg of miso-
prostol each, along with a pictorial instructional leaflet
on its use. For this research, Venture Strategies Innova-
tions (VSI) donated 6,000 misoprostol tablets.
The 566 birth attendants identified by the pregnant
women expected to carry out the deliveries were given a
1-day interactive training in 28 batches comprising
nearly 20 birth attendants per batch. This training was
spread over a period of 2 weeks. All birth attendants
were also given clean delivery kits.
II. Data collection from postpartum women and their
birth attendants
In the second phase, data collection was carried out
immediately after delivery from women who had deliv-
ered, their birth attendants, and relatives present at the
time of delivery. Separate consent forms were used for
each of the questionnaires. Written informed consent
was obtained from all the study participants in both the
intervention and comparison areas after providing them
full information about the study. Social scientists read
the informed consent to all the illiterate women who
were unable to read and sign. For all such illiterate
women, the informed consent form was verified by any
of their relatives present at that time.Safety management
Trained lady health visitors were identified in the area to
provide back-up support in case of emergency. Informa-
tion was provided to families regarding referral facilities
where 24-hour emergency services were available and
could be reached within 1 hour’s travelling time. The
identified referral facilities were the public sector Civil
Hospital in Dadu and Tehsil Hospital Mian Channu
in Khanewal.
Data management and analysis
The data were coded and entered using CSPro (version
3.2) and SPSS (version 14). All data and forms were
stored in locked cabinets at the Population Council
office in Islamabad. Results were summarized using
frequency distributions and cross tabulations. Bivariate
analysis based on intervention and comparison areas
were used to assess differences between indicators. Stat-
istical significance was established at a P value of 0.05.
Ethical consideration
This study was conducted with the approval of the Na-
tional Maternal, Neonatal and Child Health (MNCH)
Program, Ministry of Health, Government of Pakistan.
Ethical clearance was accorded by the Institutional
Review Board of the Population Council.
Results
A total of 1736 women were identified for participation
in the study (Figure 1). Out of 890 pregnant women
assigned to the intervention areas, 18 (2%) refused to
participate in the study. Another 55 were deemed ineli-
gible as they had been recommended to have facility-
based delivery by caesarean section. Forty-seven women
were referred to a health facility during labour for
obstetric complications, mainly because of prolonged
labor, and were not included in the final analysis. In
total, 770 women who delivered at home were consid-
ered eligible for taking misoprostol. In the comparison
area, out of the 846 eligible women, 20 (2%) refused to
participate in the study, and 77 women who were iden-
tified for cesarean sections were deemed ineligible.
Twenty-nine women were referred for obstetric compli-
cations, and therefore, were excluded from the final ana-
lysis, leaving 720 eligible women [9].
Characteristics of the women
The characteristics of women in both the intervention
and comparison areas were almost similar. The mean
age was 28 ± 5.7 years in the intervention areas and
28 ± 6.0 years in the comparison areas. The mean
number of live births was 3.0 ± 2.8 in the intervention
areas and 2.8 ± 2.6 in the comparison areas. Nearly half
of the respondents in both areas had made at least one
Figure 1 CONSORT flow diagram: Study profile.
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the intervention and comparison areas were uneducated
(73% and 78% respectively).
Knowledge of respondents
When the study participants were interviewed 1 month
before their expected delivery date to ascertain how muchof the information they had retained from the initial brief-
ing provided to them, 95% of the women in the interven-
tion areas knew that tablets taken orally could prevent
PPH. Approximately 52% of these women were even able
to correctly recall that the name of the drug was miso-
prostol. The other women, while aware of the misoprostol
tablets, could not mention the generic name.






Family members opposed 13 14.3
Forgot 49 53.2
TBA/dai opposed 11 11.9
Others 8 8.7
Total 92 100.0





Women who took misoprostol
correctly and reported side effects
260 40
Women who took misoprostol
incorrectly and reported side effects
17 55
Women who took misoprostol and
did not report side effects
387 60
Women who took misoprostol
incorrectly and did not report
side effects
14 45
Major side effects experienced
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ing for referral, 93% of respondents in the intervention
area and 89% in the comparison areas knew that in
case of heavy bleeding (two or more soaked cloth pads),
women must be referred to a facility within 1–2 hours.
Misoprostol use: safety, acceptability and referral
Safety
Among the 770 eligible women in the intervention areas
who delivered at home, 678 women (88%) took the
misoprostol tablets provided to them in the clean deliv-
ery kits (Table 1). Among these, 647 (84%) took the
misoprostol tablets correctly, i.e., three misoprostol
tablets ingested after the birth of the neonate, but prior
to the delivery of the placenta. The remaining 31 women
took the misoprostol tablets after the delivery of the pla-
centa. None of the women took the misoprostol tablets
before delivery. However, 92 women (12%) did not take
the misoprostol tablets (Table 2). More than half of these
respondents (49 cases) said that they forgot to take the
misoprostol tablets. Family opposition as a reason for
not taking the tablets was considered to be negligible,
with only 13 cases reporting hindrance from relatives.
Out of these, only one woman reported that her hus-
band opposed the use of misoprostol.
Side effects
Of the 647 women who took misoprostol tablets cor-
rectly (correct dose and correct time), 40% reported that
they had experienced side effects (Table 3). The majority
of women reported suffering from shivering/chills, fol-
lowed by fever and nausea. However, in all of these cases,
the symptoms were transient and did not require referral
for specialized care. Among the 31 women who took the
tablets incorrectly, 17 experienced side effects, the most
common being shivering reported by 13 women.
Acceptability
Nearly 80% of the eligible women who delivered at home
said that they would use the tablets in the future.
Seventy-four percent of women said that they would also





Eligible women who delivered at home 770 100
Women who used misoprostol tablets 678 88
-Before the baby was born 0 0
-Took 3 misoprostol tablets after
delivery of the neonate and
before delivery of the placenta
647 84
-After the placenta was delivered 31 4future, and 80% of women said that they would recom-
mend the drug to others.
Of those birth attendants in the intervention areas
who had administered misoprostol tablets, almost all of
them (98%) said that they would recommend the tablets
to other clients.PPH and referrals
The 770 women in the intervention areas and 720
women in the comparison areas who delivered at home
were asked about their perception of postpartum bloodAbdominal pain 42 16
Major side effects experienced by






Abdominal pain 3 18
Others 2 12
*Multiple response variable.
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and 82 women (11%) in the comparison areas reported
perceiving heavy postpartum bleeding short of PPH.
This heavy bleeding was characterized as blood loss
perceived as more than normal menstrual bleeding
that was not continuous and without having any clots.
Women in the intervention areas were less likely to
perceive heavy postpartum bleeding (RR: 0.45; 95%CI:
0.31-0.65) (Table 4). Similarly, women who had taken
misoprostol correctly were less likely to report having
excessive bleeding after delivery (RR: 0.43; 95%CI:
0.29-0.64) (Table 5).
Women were identified as suffering from PPH and
requiring referral by the birth attendant present at the
time of delivery if two or more cloth pads were soaked
with blood within 1 hour after delivery.
In the intervention areas, three women (0.4%) suffered
from PPH that required referral to a higher-level facility.
Out of these, two women had ingested misoprostol; 1 of
the women who had not ingested misoprostol later died
upon reaching a health facility. Two additional facility
deaths were also reported in women from the interven-
tion area; these were due to ante-partum hemorrhage
and eclampsia. In the comparison areas, five (0.6%)
women required referral for the management of PPH; of
these women, two died upon reaching the facility. In
addition, there were three more facility-based maternal
deaths due to complications of the upper respiratory
tract, uterine rupture, and exacerbation of pre-existing
cardiac disease. The cause of death was ascertained
through verbal autopsies conducted with hospital staff
where the women had been referred. In both the inter-
vention and comparison areas, no maternal deaths took
place within the home setting.
Discussion
Pakistan is one of the few countries in the region where
lowering maternal mortality continues to be a challenge.
Approximately 67% of the population resides in rural
areas, often away from health facilities, which are mostly
concentrated in urban areas. Because of the paucity of
emergency obstetric care facilities, encouraging institu-
tional deliveries at present is not a viable option for
improving maternal outcomes. To help rural women
safely deliver, the government of Pakistan launched
the national MNCH program in 2006. The aim of theTable 4 Distribution of women according to perception of he
Area Percep
Not perceived (n) Percentage (%)
Intervention 730 94.8
Comparison 638 88.6program is to train and place community midwives
(CMWs) in rural areas; however, the deployment of
these workers has been limited [14]. The CMWs still
require some time before they are fully established and
recognized as a viable and worthwhile alternative to the
existing traditional birth attendants. An interim strategy
would be to improve the safety of home-based deliveries.
The results from this study showed that through proper
counseling and training, well-entrenched behaviors and
practices of women, their families, and traditional pro-
viders could be altered. This is because our results
showed that a high percentage of women agreed to
adopt a new practice that was supported by the TBAs.
A study conducted in Tanzania also showed that TBAs
can safely use misoprostol for the treatment of PPH [3].
Our study results are similar to the results reported in
earlier studies that assessed the feasibility of administer-
ing misoprostol within the home setting. For example, in
a study carried out in West Java, Indonesia, more than
three quarters of women in the intervention area used
oral misoprostol tablets [15], whereas in a community-
based study in Afghanistan, it was found that nearly 70%
of the identified pregnant women used misoprostol [2].
Despite the transient side effects experienced by women
who took the drug, this did not prevent 80% of the
women from saying that they would take the drug for
future deliveries.
We found that three important factors contributed to
the acceptability and use of misoprostol tablets. First
and foremost was community awareness, which, to a
great extent, was facilitated by the local public sector
community-based lady health workers who helped in
targeting pregnant women and their family members.
Second, and also part of community awareness, were
discussions with community elders and influential
people. Third, counseling sessions provided accurate and
credible information directly to the women, their family
members, husbands, and birth attendants using cultur-
ally appropriate information, education and communica-
tion materials.
After providing information regarding PPH and miso-
prostol use, we interviewed the women close to their
time of delivery to determine what information they had
retained. An encouraging finding was that the majority
of respondents knew the time limit by which a woman
suffering from PPH needs to reach a facility.avy postpartum vaginal bleeding
tion of heavy bleeding
Perceived (n) Percentage (%) RR 95% CI
40 5.1 0.45 0.31-0.65
82 11.3
Table 5 Distribution of women who perceived heavy postpartum vaginal bleeding, by intake of misoprostol tablets










Intervention (incorrectly taken) 29 93.5 2 6.5 0.56 0.14-2.19
Intervention (correctly taken) 615 95.1 32 4.9 0.43 0.29-0.64
Not taken 86 93.5 6 6.5 0.57 0.25-1.27
The comparison area is the reference.
CI: Confidence Interval.
Mir et al. BMC Pregnancy and Childbirth 2012, 12:120 Page 7 of 8
http://www.biomedcentral.com/1471-2393/12/120In the current study, the high number of referrals in
the intervention and comparison areas can be attributed
to awareness created about obstetric danger signs in the
families and birth attendants. However, the high number
of maternal deaths of women, at facilities other than the
specified referral facility, highlights the dire need for
improving the quality of emergency obstetric care within
the public and private sectors, especially in rural areas.
Based on our results, we can recommend that the con-
tinuum of care approach starting from the home until
reaching a facility is the only way to reduce maternal
deaths in the rural setting.
The PPH rate in our study was lower than what we
had expected. This could be an underestimate as we
were not actually measuring blood loss. In a randomized
control trial conducted in Karachi, Pakistan, in four
hospitals, the occurrence of PPH was also found to be
low, suggesting that previous estimates had been based
on an “over-estimation” of postpartum blood loss by
hospital staff due to “incorrect measurement, resulting
in misdiagnosis, unnecessary treatment, and prolonged
hospitalization” [6].
The results from this study provide a useful addition
to the literature on the feasibility of home-based admin-
istration of misoprostol for the prevention of PPH in
resource-constrained settings.
Conclusions
This study found that misoprostol administration within
the home setting in rural communities is possible, and
proper counseling and information exchange can intro-
duce new practices in rural communities.
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